Clinical Trials Sponsored by Allergy Therapeutics

Total 10437 results

Allergy Therapeutics
Bencard Allergie GmbH

Active, not recruiting

Tyrosine Allergoid Paediatric and Adult Study

Allergic Conjunctivitis | Allergic Asthma | Allergic Rhinitis Due to Pollen

Germany
Allergy Therapeutics

Recruiting

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects (PROTECT)

Peanut Allergy

United States
Allergy Therapeutics

Completed

An Exploratory Study of PQ Grass 27600 SU

Rhinitis, Allergic, Seasonal

United States, Germany
Allergy Therapeutics

Completed

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

Seasonal Allergic Rhinitis

United States
Allergy Therapeutics

Terminated

Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen

Type I Hypersensitivity

Germany
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Type I Hypersensitivity

Canada, United States
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Seasonal Allergic Rhinitis | Rhinoconjunctivitis

United States, Germany, Austria, Hungary, Czechia, Poland
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels

Respiratory Tract Infections | Allergy | Rhinitis, Allergic | Allergic Conjunctivitis | Allergic Asthma

Germany
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Grass MATA MPL

Type I Hypersensitivity

United States, Canada, United Kingdom, Austria
Allergy Therapeutics

Completed

Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics
Ecarf Institute GmbH; Bencard Allergie GmbH

Completed

Effect of holoBLG on Cat Allergic Patients

Allergic Rhinoconjunctivitis | Allergy to Cats

Germany
Heptares Therapeutics Limited
Allergan

Completed

Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care

Alzheimer's Disease

Czechia, Poland, Slovakia, Spain
Heptares Therapeutics Limited
Allergan

Completed

A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878

Healthy

United Kingdom
Allergan
Sirna Therapeutics Inc.

Completed

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Allergy Therapeutics
SynteractHCR; Metronomia Clinical Research GMBH

Completed

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL (G104)

Seasonal Allergic Rhinitis

United States
Allergy Therapeutics
Inflamax Research Incorporated; Metronomia Clinical Research GMBH

Completed

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

Allergic Rhinitis

United States
The Center for Rheumatic Disease, Allergy, & Immunology
Grifols Therapeutics LLC

Completed

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

Infections | IgG Deficiency

United States
Allertein Therapeutics, LLC
Consortium of Food Allergy Research

Completed

Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

Hypersensitivity | Food Hypersensitivity | Peanut Hypersensitivity | Immediate Hypersensitivity

United States
National Institute of Allergy and Infectious Diseases...
Allergan

Withdrawn

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

HIV Infections
Melinta Therapeutics, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea (SOLITAIRE-U)

Uncomplicated Urogenital Gonorrhea

United States, Australia
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Abscess | Cellulitis | Surgical Site Infection | Wound Infection

United States, Bulgaria, Croatia, Estonia, Georgia, Hungary, Latvia, Romania, Russian Federation, Serbia, South Africa, Ukraine
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis

Osteomyelitis

Ukraine
Durata Therapeutics Inc., an affiliate of Allergan...

Withdrawn

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

Community Acquired Pneumonia

United States
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Abscess | Cellulitis | Surgical Site Infection | Wound Infection

United States, Bulgaria, Estonia, Hungary, Israel, Korea, Republic of, Latvia, Lithuania, Romania, Russian Federation, Slovakia, South Africa, Taiwan, Ukraine
National Institute of Allergy and Infectious Diseases...
Sanofi; ModeX Therapeutics

Terminated

Pharmacokinetics and Safety of SAR441236

HIV-1-infection

United States
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Bacterial Infections.

United States, Estonia
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Abscess | Cellulitis | Surgical Site Infection | Wound Infection

United States, Ukraine, Canada, Croatia, Georgia, Germany, Poland, Russian Federation
HAL Allergy

Completed

HAL-MPE1 First-in-human (HAL-MPE1/0043)

Peanut Allergy

Denmark
HAL Allergy

Completed

SUBLIVAC® Birch PROBE Study

Birch Pollen Allergy | Seasonal Rhinitis and/or Rhinoconjunctivitis

Germany
HAL Allergy

Completed

Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Germany
HAL Allergy

Completed

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Canada
HAL Allergy

Completed

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

Rhinitis, Allergic | Rhinoconjunctivitis, Allergic

Canada
HAL Allergy

Completed

SUBLIVAC FIX Birch Phase III Short-term Efficacy

Birch Pollen Induced Rhinitis/Rhinoconjunctivitis

Belgium, Germany, Czech Republic, Poland, Slovakia
HAL Allergy

Completed

SUBLIVAC FIX Mite Mixture Dose Tolerability Study (DTS)

House Dust Mite Allergy

Germany
HAL Allergy

Completed

SUBLIVAC FIX Phleum Pratense DT/DRF

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Germany, Poland
HAL Allergy

Completed

PURETHAL Grasses Rush Study

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Germany

Clinical Trials Sponsored by Allergy Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations